Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter

ipharmaservices
Jul 10, 2023
0 min read

Recent Posts

Germany’s Federal Ministry of Health (BMG) initiated two research funding projects to strengthen women's health | iPharmaCenter

BMG has launched two substantial research funding lines to strengthen women’s health services research in Germany, targeting patient-centered care, junior research groups, and structural capacity buil

European Commission grants approval to Sanofi's Wayrilz for refractory immune thrombocytopenia | iPharmaCenter

European Commission grants approval to Sanofi's Wayrilz (rilzabrutinib), marking the first Bruton's tyrosine kinase (BTK) inhibitor for adult patients with refractory immune thrombocytopenia (ITP). Wa

Johnson & Johnson Secures European Commission Approval for IMAAVY (Nipocalimab) to Treat Generalised Myasthenia Gravis

The European Commission has granted Marketing Authorisation to Johnson & Johnson for IMAAVY (nipocalimab), a novel FcRn-blocking antibody therapy designed to help people living with generalised myasth

iPharmaCenter

ipharmacenter Consulting services

Switzerland drug approvals | Swissmedic news | Blogs | 2023 | iPharmaCenter

Recent Posts

Comments